One of the current goals in vaccine development is the noninvasive administration of protective antigens via mucosal surfaces. In this context, the gut-associated lymphoid tissues have already been extensively explored. Vaccination via the nasal route has only recently been the focus of intensive investigation, and no live vector specifically designed for the respiratory mucosa is yet available. In this study we show that intranasal administration of the recombinant Bordetella pertussis BPGR60, producing the Schistosoma mansoni 28-kDa glutathione S-transferase (Sm28GST) protective antigen fused to filamentous hemagglutinin, induces priming in mice for the production of serum antibodies. In addition to significant levels of anti-Sm28GST immunoglobulin A (IgA) antibodies, high levels of anti-Sm28GST serum antibodies were obtained after intranasal boost with the purified antigen or infection with S. mansoni following intranasal priming with BPGR60. These antibodies were of the IgG1, IgG2a, and IgG2b isotypes, suggesting a mixed immune response. No priming was observed in animals that had received nonrecombinant B. pertussis or purified Sm28GST, indicating specific priming by BPGR60. This priming was also evident in immune protection against S. mansoni challenge. Significant protection against worm burden and egg output was obtained in mice primed with BPGR60 and intranasally boosted with purified Sm28GST. A lower but still significant degree of protection against egg output was also obtained in mice infected with a single dose of BPGR60. These results indicate that intranasal administration of recombinant B. pertussis can prime for serum antibody responses against a foreign antigen and for heterologous protection.
One of the main objectives in the current development of new vaccines is the induction of strong mucosal and systemic immune responses against protective antigens delivered by the mucosal route. This route of vaccination has, in principle, the advantage of easy administration in a noninvasive fashion and thereby avoidance of risks of contamination caused by injection. A promising approach for the mucosal delivery of vaccines is the use of live vectors expressing genes that encode protective antigens. Various live vectors producing heterologous antigens, such as Salmonella and Mycobacterium bovis BCG, have been developed in recent years (7, 13, 29) . We have recently described the use of Bordetella pertussis to deliver heterologous antigens to the mucosa-associated lymphoid tissue of the respiratory tract via intranasal administration (22) .
B. pertussis, the etiologic agent of whooping cough, is a highly contagious microorganism that produces several adhesins, among which filamentous hemagglutinin (FHA) is the most important (for a review, see reference 15) . Mature FHA is a 220-kDa protein that is both surface associated and secreted into the extracellular environment. Therefore, a foreign protein fused to FHA would be expected to be exposed on the bacterial surface and/or to be secreted. Furthermore, in view of its importance in the adherence of B. pertussis (12, 21, 28) , FHA is included as an important antigen in the new acellular vaccines against whooping cough (9) . Both mice and children infected with B. pertussis or immunized with whole-cell pertussis vaccines produce anti-FHA immunoglobulin G (IgG) antibodies (1, 20) . High titers of anti-FHA IgA are also detected in the nasal secretions of convalescing patients after natural B. pertussis infections (16, 26) . Moreover, the anti-FHA IgG and IgA antibody levels in the respiratory mucosa of mice infected intranasally with virulent B. pertussis (1) or immunized mucosally with purified FHA (24) are of long duration. The high infectivity of B. pertussis, the important level of secretion of FHA, and its strong immunogenicity after nasal administration have prompted us to use surface-exposed FHA for the presentation of heterologous antigens by recombinant B. pertussis. We have recently shown that a single intranasal administration of recombinant B. pertussis producing at its surface the 28-kDa glutathione S-transferase of Schistosoma mansoni (Sm28GST) genetically fused to FHA resulted in significant levels of anti-Sm28GST IgA antibodies in the bronchoalveolar lavage (BAL) fluids of mice (22) . However, no serum anti-Sm28GST antibodies were detected. Here we demonstrate that in spite of the lack of anti-Sm28GST serum antibodies after intranasal administration of the recombinant B. pertussis strain, the mice were primed for the production of serum antibodies that were readily detectable after an intranasal boost of purified Sm28GST without adjuvant or after infection with S. mansoni. Sm28GST has been shown to confer protective immunity in several animal models, including primates (3) (4) (5) 10) , especially against the pathology-causing egg output and egg viability. We therefore also assessed the intranasal priming effect of the administration of recombinant B. pertussis on protective immunity against egg output and worm burden. The results indicate that intranasal priming with the recombi-nant B. pertussis resulted in a significant reduction of intestinal egg output and worm burden after challenge with S. mansoni.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Streptomycin-and nalidixic acidresistant (Sm r Nal r ) B. pertussis BPSM (18) and recombinant B. pertussis BPGR60 (Sm r Nal r ) containing an in-frame BamHI fragment coding for Sm28GST in the fhaB gene (22) were grown at 36ЊC on Bordet-Gengou agar (Difco, Detroit, Mich.) supplemented with 5% glycerol and 20% defibrinated sheep blood and containing 100 g of streptomycin (Sigma, St. Louis, Mo.) per ml and 25 g of nalidixic acid (Sigma) per ml.
Antigens. Recombinant Sm28GST (rSm28GST) was produced in Escherichia coli TGE901 containing pTG54 (provided by Transgène S.A., Strasbourg, France) and was affinity purified as previously described (27) . FHA was purified as described elsewhere (17) from B. pertussis BPRA, a strain in which the pertussis toxin gene had been deleted (2) .
Intranasal infection of mice. After 48 h of culture, B. pertussis was resuspended at a concentration of approximately 10 8 CFU/ml in sterile phosphate-buffered saline (PBS). Sublethal infections were performed by the intranasal route with 50 l of the bacterial suspension deposited in the nostrils of 4-week-old OF1 mice (Iffa Credo, L'Arbesle, France) anesthetized with 200 l (per 10 g of body weight) of a solution of 5% sodium pentobarbital (Sanofi, Libourne, France) given intraperitoneally. To assess the initial numbers of viable B. pertussis in the lungs, five infected mice were killed 3 h after exposure. The lungs were removed aseptically and homogenized in 5 ml of PBS. Serially diluted homogenates from individual lungs were plated onto Bordet-Gengou agar, and the number of CFU was counted after 3 to 4 days of incubation at 36ЊC.
Collection of fluids. Mice under anesthesia were bled by retro-orbital plexus puncture, the trachea was cannulated, and BAL fluids were recovered by three consecutive lavages with 0.5 ml of PBS. BAL fluids were centrifuged at 4,000 ϫ g for 10 min to remove cells. Sera and BAL fluids were stored at Ϫ20ЊC until assayed for the presence of specific antibodies.
Serum and lung antibody determination. The level of antibodies to FHA and Sm28GST in sera and BAL fluids was determined by enzyme-linked immunosorbent assays (ELISA). Microtiter plates (Immulon III; Dynatech Laboratories, McLean, Va.) were coated for 2 h 30 min at 37ЊC with 50 l of 10-g/ml FHA or Sm28GST diluted in PBS per well. For serum antibody determinations, pooled serum samples serially diluted in PBS containing 0.1% Tween (PBS/Tw) or 0.1% Tween plus 0.5% gelatin (PBS/Tw/g) were added to the coated plates after three washes in PBS/Tw and were incubated overnight at 4ЊC. The plates were incubated for 30 min at 37ЊC and washed three times in PBS/Tw before addition of goat anti-mouse IgG-horseradish peroxidase conjugate (Southern Biotechnology Associates, Inc., Birmingham, Ala.) and incubation for 1 h 30 min at 37ЊC. For lung antibody determination, the BAL fluids were added to the coated plates and incubated for one night at 4ЊC in PBS/Tw after 30-min saturation with PBS containing 0.5% gelatin and three washes with PBS/Tw. Antimouse IgA-biotin conjugates (Amersham, Buckinghamshire, United Kingdom) diluted in PBS/Tw/g were added and incubated for 1 h 30 min at 37ЊC. After five washes with PBS/Tw, the streptavidin-horseradish peroxidase conjugate (Amersham) was added. After six washes with PBS/Tw, 1 mg of o-phenylenediamine (Sigma) per ml in 0.1 M sodium phosphate buffer (pH 5.5) containing 0.03% H 2 O 2 was added and incubated for 30 min at 37ЊC. The reaction was stopped by the addition of 50 l of 2 N HCl. The optical density (OD) was measured with a Titertek Multiscan MCC/340 reader at 492 nm, and a linear regression curve of log OD versus the serum dilution was plotted. Results were expressed in titers, reported as the reciprocal of the dilution giving an OD three times that of the conjugate control for the pooled serum samples or twice that of the conjugate control for the pooled BAL fluid samples.
S. mansoni challenge. The life cycle of the Guadeloupe S. mansoni strain (kindly provided by C. Combes) was maintained by using hamsters as definitive hosts and Biomphalaria glabrata snails as intermediate hosts. Mice were exposed percutaneously (25) to 70 S. mansoni cercariae. Whole-body perfusion was carried out on day 42 or 49 after infection, and the worm burden was determined by counting with a light microscope. At the time of perfusion, the small intestine and the liver were collected and digested with 4% potassium hydroxide to estimate the numbers of eggs deposited in these tissues. The percentage of protection was calculated by the formula (A Ϫ B/A) ϫ 100, where A is the average parasite burden of the control group of 14 to 16 mice and B is that of the experimental group of 9 to 12 mice. Student's t test was used for the statistical analysis.
RESULTS

Induction of anti-Sm28GST immune response after priming with recombinant B. pertussis and intranasal boosting with
purified Sm28GST. The mucosal immune response obtained after a single nasal administration of B. pertussis BPGR60 producing the FHA-Sm28GST hybrid protein has been previously evaluated (22) . Mice receiving BPGR60 produced high levels of anti-FHA serum antibodies but insignificant levels of anti-Sm28GST serum antibodies (see Table 1 ) that did not increase even 3 months after bacterial infection. However, as previously shown (22) , the BAL fluids contained significant levels of anti-Sm28GST IgA and IgG that lasted for more than 1 month after infection.
Although serum anti-Sm28GST antibody levels were insignificant after intranasal administration of BPGR60, we wished to investigate whether infection with this strain could nevertheless prime mice for a secondary serum antibody response when boosted with the purified antigen. Two months after the primary immunization with BPGR60, when clearance of bacteria was completed (22) , the mice were boosted by a single intranasal administration of 20 g of purified rSm28GST without adjuvant. Control mice were either not preinfected or preinfected with wild-type B. pertussis BPSM. Two weeks after the boost, a strong antibody response to Sm28GST was detected in the serum of only those mice that had previously received BPGR60 (Fig. 1a ). No anti-Sm28GST antibody response was detected in the serum of naive or BPSM-infected mice after a single administration of rSm28GST. Furthermore, a second intranasal administration of the purified rSm28GST to uninfected mice did not result in the production of detectable serum anti-Sm28GST antibodies (titer Ͻ 20). These results indicate that the administration of BPGR60 is able to prime the mice for a strong anti-Sm28GST-specific immune response in the serum after intranasal boosting with purified antigen without adjuvant.
The isotypic distribution of the antibody response against Sm28GST and against FHA was also evaluated. In the serum of mice that received BPGR60 and then rSm28GST, the anti-Sm28GST response showed a high level of specific IgG1, IgG2a, and IgG2b isotypes ( Table 1 ). In addition, a significant level of serum anti-Sm28GST IgA which was as high as the level of anti-FHA serum IgA was detected. The isotypic pattern of the anti-FHA response showed high levels of IgG1, IgG2a, and IgG2b isotypes. A comparable anti-FHA antibody response was obtained after administration of wild-type B. pertussis, with or without administration of rSm28GST. Furthermore, no significant change in the level of anti-FHA serum antibodies was observed after the boost with rSm28GST.
The level of anti-Sm28GST IgA in the BAL fluids also increased in BPGR60-primed mice boosted with 20 g of rSm28GST, with maximal specific IgA production 2 weeks after the boost (Fig. 1b ).
Previous results (22) have shown that BPGR60 was undetectable in the lungs 5 weeks after infection. However, it has been shown that B. pertussis can be internalized and survive within resident macrophages (8, 23) . Therefore, the stress of intranasal administration might restore bacterial growth. To test the possible impact of intranasal administration, the lungs of mice intranasally boosted 2 months after infection with BPGR60 were removed 1 week later, and no viable bacteria were detected. Since B. pertussis is known to cause a strictly localized respiratory-tract infection, it is unlikely that BPGR60 disseminates at distal sites. The increase in the antibody level against Sm28GST therefore appears to result from the boost with rSm28GST following priming with BPGR60.
Secondary immune response after infection with S. mansoni. In mice a serum antibody response against Sm28GST during experimental S. mansoni infection can be detected only 9 weeks after infection (8a) . In order to evaluate the capacity of the parasite to boost an immune response to Sm28GST in BPGR60-primed animals, mice were percutaneously infected with 70 S. mansoni cercariae 2 months after administration of BPGR60. Twenty days later, we detected low levels of serum VOL. 65, 1997 PRIMING WITH RECOMBINANT B. PERTUSSIS anti-Sm28GST IgG which gradually increased up to the titer of 843, 42 days after parasite infection (Fig. 2a ). The isotypic profile of this immune response was found to be similar to that obtained after the intranasal boost with rSm28GST (data not shown). In control mice that received either PBS or B. pertussis BPSM prior to infection with S. mansoni, no antibody response against Sm28GST was observed in the serum up to 42 days after S. mansoni infection. Ten days after cercarial exposure, we also observed an increase in the level of anti-Sm28GST IgA in the BAL fluids of mice primed with BPGR60 (Fig. 2b) . The level decreased 28 days after the parasite infection. No detectable antibody to Sm28GST was found in infected control mice. The challenge infection with the parasite thus appeared to boost both serum and pulmonary immune responses to Sm28GST in mice primed with the recombinant B. pertussis strain.
Protection against S. mansoni after intranasal infection with BPGR60. It has previously been shown that immunization with Sm28GST can result in significant protection against S. mansoni challenge in several animal models (3) (4) (5) 10) . It is of particular interest that such immunization may reduce parasite fecundity and egg viability (4). Since granuloma formation around the deposited eggs is the major pathogenic trait of S. mansoni infection, this property of Sm28GST immunization may not only limit the spread of the infection but also lessen the pathological features. Even a relatively modest decrease in egg output may have a significant impact in the decrease of pathology. Since maximal protection conferred by Sm28GST in the mouse usually does not exceed 40 to 50%, the mouse model may not be the most appropriate one to evaluate protective efficacy of Sm28GST-based vaccines. We nevertheless wanted to assess whether intranasal administration of BPGR60 and subsequent intranasal boosting with purified rSm28GST have any protective effect in mice. A challenge with 70 cercariae was therefore performed 1 week after the boost when the levels of antibodies to Sm28GST in the serum and the BAL fluids were high (Fig. 1) . A significant reduction in worm burden (about 33%) ( Table 2 ) was obtained in the group of these mice. In addition, a significant reduction of the number of tissue eggs (42%) was obtained. In mice that had received only BPGR60, the worm number was slightly reduced (about 16%), although this was not statistically significant. However, in this group, a weak reduction in tissue egg numbers was recorded (28%, P ϭ 0.027). A single intranasal administration of rSm28GST or wild-type B. pertussis did not show any significant protective effect. However, the nasal administration of the wild-type B. pertussis followed by a boost with rSm28GST was associated with a small but nonsignificant reduction in worm burden and egg output. Pooled sera of mice immunized with BPGR60 alone or with BPGR60 followed by rSm28GST and collected 3 days before perfusion contained anti-Sm28GST IgG titers of 815 and 1,128, respectively. Pooled sera from the other groups of mice showed titers lower than 160.
DISCUSSION
We have previously shown that intranasal infection with a recombinant B. pertussis strain producing Sm28GST fused to FHA at the surface of the microorganism resulted in significant anti-Sm28GST IgA in the BAL fluid without detectable levels of specific serum antibodies (22) . The aim of this study was to evaluate the priming potential of intranasal administration of this strain for serum antibodies and protection against infection by S. mansoni. This parasite model was chosen because the mucosal route of immunization may be most appropriate for vaccination in developing countries particularly affected by parasitic diseases. Here, we found that BPGR60primed mice intranasally boosted with purified rSm28GST produced high titers of anti-Sm28GST serum antibodies. These serum antibodies against Sm28GST were still found 3 months after the boost, whereas no antibody response to Sm28GST was detected in the sera of mice even after two nasal immunizations with rSm28GST after a one-month interval or after priming with the nonrecombinant B. pertussis parent strain, BPSM. The strong specific antibody response observed after boosting with rSm28GST can thus be attributed to a priming effect of infection with BPGR60. In addition, anti-Sm28GST IgA antibodies were found in BAL fluids of BPGR60-immunized mice, which may trap the antigen as IgAantigen complexes. It has been shown that such IgA-antigen complexes adhere to M cells of Peyer's patches much more efficiently than do the uncomplexed antigens (30) . M cells are involved in the transcytosis of antigens across the mucosal epithelium. Since they are found in mucosal surfaces of both the respiratory tract and the gut-associated lymphoid tissue (14, 19) , this uptake mechanism of IgA-antigen complexes could also occur with M cells in bronchus-associated lymphoid tissue and may increase M-cell transcytosis of the antigen, enhance antigen presentation via IgA-mediated Fc␣ receptor interaction on the surface of cells present in the mucosa-associated lymphoid tissue (14) , and therefore considerably contribute to the secondary immune response.
The anti-Sm28GST isotype profile showed the presence of IgG1, IgG2a, and IgG2b as well as IgA in the sera of mice infected with BPGR60 and then boosted with rSm28GST, suggestive of a mixed Th1-Th2-type response. In order to confirm the involvement of the two T-cell subpopulations, studies to investigate the cytokine secretion profiles of antigen-stimulated cells are under way. The isotype distribution of anti-FHA antibodies in the sera of BPGR60-infected mice showed slight differences compared to the anti-Sm28GST response but also corresponded to a mixed profile as defined by the presence of IgG1, IgG2a, and IgG2b. A significant amount of serum anti-FHA IgA was also detected in these mice. The antibody response to FHA was quantitatively and qualitatively similar to that found in mice infected with the wild-type B. pertussis, indicating that the fusion of Sm28GST to FHA did not modify the immunogenicity of the FHA.
However, serum antibodies to Sm28GST were found only after intranasal boost with recombinant antigen, whereas serum anti-FHA antibodies were detected after a single BPGR60 administration. This discrepancy could be the result of the intrinsic characteristics of the FHA-Sm28GST hybrid protein. FHA (220 kDa) is a much larger molecule than Sm28GST (28 kDa), suggesting a higher number of epitopes on FHA compared to Sm28GST. In addition, FHA seems to be a much more immunogenic protein than Sm28GST, since a similar level of serum antibody response specific for each antigen is obtained after nasal administration of both purified antigens associated in a liposome in an FHA/Sm28GST ratio of 1 mol/ 100 mol (19a) .
When the mice were challenged with S. mansoni cercariae after a single infection with BPGR60, a serum immune response against Sm28GST was detectable 3 weeks after challenge, and its level increased thereafter continuously for at least 42 days. This is in sharp contrast to the lack of detectable anti-Sm28GST antibodies in parasite-infected mice that had previously received either PBS or BPSM and again confirmed that BPGR60 is able to prime mice for a specific serum anti-Sm28GST antibody response occurring after challenge. The slow release of Sm28GST by the parasite, as well as the antigens released by killed worms, might explain the immune response observed in these BPGR60-primed mice infected by S. mansoni.
Previous experiments (3, 4) in the mouse model have shown that two subcutaneous immunizations of rSm28GST with either aluminum hydroxide or complete Freund's adjuvant as the adjuvant resulted in a reduction in worm burden and egg counts after experimental S. mansoni infection. However, in a OF1 mice were intranasally immunized with 5 ⅐ 10 6 CFU of recombinant BPGR60 or wild-type BPSM and intranasally boosted 2 months later with 20 g of rSm28GST or with PBS. The sera were collected 14 days later. The isotypic distribution of the antibody responses in the pooled serum samples was evaluated by ELISA. this model the levels of protection were at best in the range of about 40%. Here, we found that intranasal immunization of mice with BPGR60 followed by an intranasal boost with purified rSm28GST resulted in a similar level of protection against challenge with S. mansoni performed 1 week after the boost. This protection resulted in the reduction of worm burden as well as of egg charge. It appears therefore that the mucosal administration of an Sm28GST-based vaccine using priming by recombinant B. pertussis may protect as effectively as subcutaneously administered vaccines. In addition, we observed 34.2% protection (P ϭ 0.0048) when the animals were challenged 14 weeks after the boost, at a time when the level of anti-Sm28GST antibodies had strongly decreased (titer of 258). In contrast, a single nasal administration of purified rSm28GST did not show any protective effect, nor did it induce priming for a secondary response with either rSm28GST or S. mansoni infection.
These observations indicate that even at low levels of antibodies, BPGR60-primed mice may be at least partially protected. This contention was further supported by the finding that although a single nasal administration of BPGR60 did not induce an antibody response to Sm28GST in the serum before S. mansoni infection, a reduction of the egg charge was nevertheless observed, accompanied by a slight but nonsignificant reduction in worm burden. The difference in the effect on worm burden and on egg output after only priming with BPGR60 may be the result of a differential effect of boosting by infection with S. mansoni on these two parameters. It is tempting to speculate that infection with S. mansoni boosted the anti-Sm28GST antibody level in such a manner that it had a more profound bearing on fecundity than on worm viability. This may be particularly interesting since pathology in schistosomiasis is mainly associated with inflammation around the parasite eggs deposited in the host tissues. Even a decrease in egg number by a factor of 2 would significantly decrease pathology (6) . This suggests that noninvasive intranasal priming by live vectors such as B. pertussis has some potential in diminishing pathology and perhaps transmission. We showed thus for the first time that it is possible to induce a protective immune response against S. mansoni after nasal immunization using Sm28GST, one of the candidate molecules against schistosomiasis selected by the World Health Organization (31) . In addition, the presence of specific serum anti-Sm28GST IgA in BPGR60-immunized mice is in favor of a protective efficacy of our strategy. Indeed, it has recently been found that the acquisition of resistance to reinfection in human populations is closely associated with the presence of anti-Sm28GST IgA (11) .
In conclusion, this study indicates that intranasal immunization with a recombinant B. pertussis strain primes mice both for a specific serum immune response against a heterologous protein fused to FHA and for protection. The genetic stability of the chromosomal construction used here, as well as its potential to deliver other foreign antigens, makes recombinant B. pertussis a novel promising candidate as a live vector for nasal vaccination. Of course, since BPGR60 is a fully virulent B. pertussis strain, it cannot be administered as a live vaccine to humans. We are therefore currently developing new, attenuated strains of B. pertussis with the hope of maintaining immunogenicity against foreign antigens while eliminating the pathogenicity of the vector. 
